A complete list of publications by Dr. James Nyagwange. Use the filters to refine by year, journal or keyword.

No publications match those filters.

1. 2026
   Comparison of capillary microsampling and venous blood for multi-pathogen serosurveillance

   Ombati, R. Kimani, M. Akech, D. Kutima, et al.

   Sci Rep. 2026

   View abstract DOI PubMed
2. 2026
   A natural experiment in Kenya reveals durable immunosuppressive effects of early childhood malaria: a longitudinal cohort study

   Safari, M. S. Makori, T. O. Gicheru, E. T. Mburu, et al.

   Elife. 2026; 14

   View abstract DOI PubMed
3. 2026
   Longitudinal evidence of differential pertussis antibody durability following natural infection among vaccinated children living in contrasting malaria transmission settings in coastal Kenya

   Safari, M. S. Gicheru, E. T. Mburu, M. W. Makori, et al.

   Vaccine. 2026; 88:128837

   View abstract DOI PubMed
4. 2026
   Heart-nosed bat alphacoronaviruses use human CEACAM6 to enter cells

   Gallo, G. Di Nardo, A. Lugano, D. Roberts, et al.

   Nature. 2026; 653:180-189

   View abstract DOI PubMed
5. 2026
   Longitudinal Epidemiology and Variant Dynamics of SARS-CoV-2 in Coastal Kenya (2020-2025): Clinical Features and Wave Patterns

   Lambisia, A. W. Nyiro, J. Githinji, G. Katama, et al.

   Open Forum Infect Dis. 2026; 13:ofag084

   View abstract DOI PubMed
6. 2025
   Assessing the Impact of SARS-CoV-2 Spike Mutations on Antibody Binding: A Comparative Assessment of the Wuhan and JN.1 Variants' Full-Length Spikes in a Multiplex Luminex Assay

   Waweru, G. Nyakundi, R. Kutima, B. Owuor, et al.

   Viruses. 2025; 17

   View abstract DOI PubMed
7. 2025
   Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave

   Lambisia, A. W. Katama, E. N. Moraa, E. Mwita, et al.

   BMC Glob Public Health. 2025; 3:80

   View abstract DOI PubMed
8. 2023
   Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study

   Kimotho, J. Sein, Y. Sayed, S. Shah, et al.

   Wellcome Open Res. 2023; 8:350

   View abstract DOI PubMed
9. 2024
   Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration

   Kagucia, E. W. Voller, S. Ziraba, A. K. Bigogo, et al.

   Gates Open Res. 2024; 8:60

   View abstract DOI PubMed
10. 2024
    Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya

    Lugano, D. Kutima, B. Kimani, M. Sigilai, et al.

    BMC Infect Dis. 2024; 24:1474

    View abstract DOI PubMed
11. 2024
    Comparative performance of the InBios SCoV-2 Detect (TM) IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations

    Kutima, B. Kagucia, E. W. Mwai, K. Kimani, et al.

    Wellcome Open Res. 2024; 9:349

    View abstract DOI PubMed
12. 2023
    A Customizable Suite of Methods to Sequence and Annotate Cattle Antibodies

    Ramirez Valdez, K. Nzau, B. Dorey-Robinson, D. Jarman, et al.

    Vaccines (Basel). 2023; 11

    View abstract DOI PubMed
13. 2023
    Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro

    Nyagwange, J. Kutima, B. Mwai, K. Karanja, et al.

    Int J Infect Dis. 2023; 127:11-16

    View abstract DOI PubMed
14. 2023
    SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022

    Kagucia, E. W. Ziraba, A. K. Nyagwange, J. Kutima, et al.

    Influenza Other Respir Viruses. 2023; 17:e13173

    View abstract DOI PubMed
15. 2023
    Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

    Hamaluba, M. Sang, S. Orindi, B. Njau, et al.

    Wellcome Open Res. 2023; 8:182

    View abstract DOI PubMed
16. 2023
    Symptom prevalence and secondary attack rate of SARS-CoV-2 in rural Kenyan households: A prospective cohort study

    Gallagher, K. E. Nyiro, J. Agoti, C. N. Maitha, et al.

    Influenza Other Respir Viruses. 2023; 17:e13185

    View abstract DOI PubMed
17. 2022
    Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya

    Nyagwange, J. Ndwiga, L. Muteru, K. Wamae, et al.

    Wellcome Open Res. 2022; 7:69

    View abstract DOI PubMed
18. 2022
    Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations

    Nyagwange, J. Kutima, B. Mwai, K. Karanja, et al.

    J Clin Virol. 2022; 146:105061

    View abstract DOI PubMed
19. 2022
    Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020-21

    Lucinde, R. K. Mugo, D. Bottomley, C. Karani, et al.

    PLoS One. 2022; 17:e0265478

    View abstract DOI PubMed
20. 2022
    Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya

    Etyang, A. O. Lucinde, R. Karanja, H. Kalu, et al.

    Clin Infect Dis. 2022; 74:288-293

    View abstract DOI PubMed
21. 2022
    SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021

    Etyang, A. O. Adetifa, I. Omore, R. Misore, et al.

    PLOS Glob Public Health. 2022; 2:e0000883

    View abstract DOI PubMed
22. 2021
    Prevalence of anti-SARS-CoV-2 IgG antibodies among Kenyan blood donors between June and August 2021.

    Uyoga, S. Otiende, M. Adetifa, I. M. O. Karanja, et al.

    1st International Conference on Public Health in Africa (CPHIA). 2021

    View abstract
23. 2021
    Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors

    Uyoga, S. Adetifa, I. M. O. Karanja, H. K. Nyagwange, et al.

    Science. 2021; 371:79-82

    View abstract DOI PubMed
24. 2021
    Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations.

    Nyagwange, J. Kutima, B. Mwai, K. Karanja, et al.

    1st International Conference on Public Health in Africa (CPHIA). 2021

    View abstract
25. 2021
    Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya

    Kagucia, E. W. Gitonga, J. N. Kalu, C. Ochomo, et al.

    Open Forum Infect Dis. 2021; 8:ofab314

    View abstract DOI PubMed
26. 2021
    High anti-SARS-CoV-2 IgG antibody seroprevalence among long-distance trucking crews in Kenya within one year of the COVID-19 pandemic.

    Kagucia, E. W. Gitonga, J. N. Kalu, C. Kuya, et al.

    1st International Conference on Public Health in Africa (CPHIA). 2021

    View abstract
27. 2021
    Serosurveillance for SARS-CoV-2 Antibodies in a cohort of Health Care Workers in Kenya.

    Etyang, A. O. Lucinde, R. Gitonga, J. N. Kalu, et al.

    1st International Conference on Public Health in Africa (CPHIA). 2021

    View abstract
28. 2021
    COVID-19 transmission dynamics underlying epidemic waves in Kenya

    Brand, S. P. C. Ojal, J. Aziza, R. Were, et al.

    Science. 2021; 374:989-994

    View abstract DOI PubMed
29. 2021
    Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels

    Bottomley, C. Otiende, M. Uyoga, S. Gallagher, et al.

    Nat Commun. 2021; 12:6196

    View abstract DOI PubMed
30. 2021
    Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya

    Adetifa, I. M. O. Uyoga, S. Gitonga, J. N. Mugo, et al.

    Nat Commun. 2021; 12:3966

    View abstract DOI PubMed